Welcome to our dedicated page for AWAKN LIFE SCIENCES news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on AWAKN LIFE SCIENCES stock.
Awakn Life Sciences Corp. news covers the company's historical role as a clinical-stage biotechnology issuer developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder. Recurring updates included R&D programs such as AWKN-001 and AWKN-002, regulatory interactions, clinical-development planning, and financing arrangements supporting research activity.
The company's recent corporate news also documents its completed statutory arrangement and sale to Solvonis Therapeutics plc, including shareholder approval, supplemental disclosure tied to minority-securityholder protections, treatment of common shares and equity awards, and related warrant adjustments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.